Denali Therapeutics' GAAP loss for 9M 2021 was $215.32 million, up 23.9% from $173.749 million in the prior year. Revenue increased 91.8% to $36.147 million from $18.844 million a year earlier.
Denali Therapeutics' GAAP loss for 9M 2021 was $215.32 million, up 23.9% from $173.749 million in the prior year. Revenue increased 91.8% to $36.147 million from $18.844 million a year earlier. 
denalitherapeutics.com
English (US) 